Dendreon's CEO Exits: Is this the Beginning of the End?
Dendreon CEO John Johnson announced yesterday that he is stepping down for "personal reasons." His departure comes ahead of a large company debt payment. Could Dendreon be on the precipice of bankruptcy?
Tuesday’s Top Biotech Stories: Achillion, Receptos, and Dendreon
Achillion, Receptos, and Dendreon could all make waves in biotech headlines this Tuesday morning.
Why Wall Street Hates Dendreon Corp.
Stocks with heavy short interest might signal that something is terribly wrong with a company. Dendreon Corp. sports one of the highest short interests among health-care stocks. Why are short-sellers so bearish on this small-cap biotech?
Biotech Dilemma: When a Loan Isn't Non-Dilutive
Retrophin takes out a convertible note. As Dendreon has shown, taking on debt can be dangerous if the company can't pay it back. Investors should look for companies like Seattle Genetics and Regeneron Pharmaceuticals that have assets they can sell to slow the cash burn.